{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:04:32Z","timestamp":1772445872224,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Response assessment in the treatment of metastatic sarcoma primarily depends on imaging, as no established clinical or serological biomarkers reliably predict survival outcomes. This study evaluates the utility of Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in predicting overall survival (OS) in sarcoma patients with pulmonary metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We selected consecutive study subjects from a prospective registry based on the following criteria: (1) available CT imaging at first diagnosis of pulmonary metastases from sarcoma, (2) available follow-up CT imaging within 16 weeks of systemic therapy initiation, (3) documentation of OS. Volumetric segmentation of up to 5 lung metastases was performed over time. Progressive disease (PD) was defined as increase of the unidimensional sum of lesions\u2009\u2265\u200920% or appearance of new metastases according to RECIST v1.1. Kaplan-Meier survival analyses were performed. P values\u2009&lt;\u20090.05 were considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-two patients were included (median age: 58 years; 50% female). Average time of follow-up CT was 67 days after baseline imaging. Patients with PD on first follow-up imaging (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924; 26%) showed significantly shorter OS (13.9 months vs. 29.3 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). The unidimensional growth threshold of 20% proposed by RECIST did not stratify OS (14.6 months vs. 26.8 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.221). The appearance of new metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916; 17%) indicated significantly shorter OS (7.8 months vs. 27.0 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and was frequently observed even in patients with decreasing size of existing metastases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097; 8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Imaging progression patterns of pulmonary metastatic sarcoma demonstrate distinct associations with OS, highlighting the need for sarcoma-specific adaptations to established response criteria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01012-0","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:57:32Z","timestamp":1772099852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of RECIST v1.1 for predicting overall survival in sarcoma patients with pulmonary metastasis"],"prefix":"10.1186","volume":"26","author":[{"given":"Lukas","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Klambauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Klinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeel","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Mehrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701\u201311. https:\/\/doi.org\/10.1056\/NEJMra041866.","journal-title":"N Engl J Med"},{"key":"1012_CR2","doi-asserted-by":"crossref","unstructured":"Billingsley KG, Lewis JJ, Leung DHY, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999;85:389\u201395. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990115)85:2<389::Aid-cncr17>3.0.Co;2-j.","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<389::AID-CNCR17>3.0.CO;2-J"},{"key":"1012_CR3","doi-asserted-by":"publisher","first-page":"20201109","DOI":"10.1259\/bjr.20201109","volume":"94","author":"A Saifuddin","year":"2021","unstructured":"Saifuddin A, Shafiq H, Rajakulasingam R, Tan A, O\u2019Donnell P, Khoo M. A review of staging chest CT in trunk and extremity soft tissue sarcoma. Br J Radiol. 2021;94:20201109. https:\/\/doi.org\/10.1259\/bjr.20201109.","journal-title":"Br J Radiol"},{"key":"1012_CR4","doi-asserted-by":"publisher","first-page":"20210088","DOI":"10.1259\/bjr.20210088","volume":"94","author":"A Saifuddin","year":"2021","unstructured":"Saifuddin A, Baig MS, Dalal P, Strauss SJ. The diagnosis of pulmonary metastases on chest computed tomography in primary bone sarcoma and musculoskeletal soft tissue sarcoma. Br J Radiol. 2021;94:20210088. https:\/\/doi.org\/10.1259\/bjr.20210088.","journal-title":"Br J Radiol"},{"key":"1012_CR5","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1002\/ijc.31286","volume":"142","author":"LH Lindner","year":"2018","unstructured":"Lindner LH, Liti\u00e8re S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Int J Cancer. 2018;142:2610\u201320. https:\/\/doi.org\/10.1002\/ijc.31286.","journal-title":"Int J Cancer"},{"key":"1012_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BLO.0b013e31805d8606","volume":"459","author":"S Rissing","year":"2007","unstructured":"Rissing S, Rougraff BT, Davis K. Indeterminate pulmonary nodules in patients with sarcoma affect survival. Clin Orthop Relat Res. 2007;459:118\u201321. https:\/\/doi.org\/10.1097\/BLO.0b013e31805d8606.","journal-title":"Clin Orthop Relat Res"},{"key":"1012_CR7","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1245\/s10434-011-1705-4","volume":"18","author":"HS Cho","year":"2011","unstructured":"Cho HS, Park IH, Jeong WJ, Han I, Kim HS. Prognostic value of computed tomography for monitoring pulmonary metastases in soft tissue sarcoma patients after surgical management: a retrospective cohort study. Ann Surg Oncol. 2011;18:3392\u20138. https:\/\/doi.org\/10.1245\/s10434-011-1705-4.","journal-title":"Ann Surg Oncol"},{"key":"1012_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00000658-199905000-00002","volume":"229","author":"KG Billingsley","year":"1999","unstructured":"Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602\u201310. https:\/\/doi.org\/10.1097\/00000658-199905000-00002. discussion 610\u2009\u2013\u2009602.","journal-title":"Ann Surg"},{"key":"1012_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mdy052","volume":"29","author":"Trans-Atlantic Retroperitoneal Sarcoma Working Group","year":"2018","unstructured":"Trans-Atlantic Retroperitoneal Sarcoma Working Group. Electronic address ambbc. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29:857\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdy052.","journal-title":"Ann Oncol"},{"key":"1012_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1012_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"key":"1012_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.clon.2017.04.002","volume":"29","author":"H Choi","year":"2017","unstructured":"Choi H. Role of Imaging in Response Assessment and Individualised Treatment for Sarcomas. Clin Oncol (R Coll Radiol). 2017;29:481\u20138. https:\/\/doi.org\/10.1016\/j.clon.2017.04.002.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1012_CR13","doi-asserted-by":"publisher","unstructured":"Litiere S, Bogaerts J. Imaging endpoints for clinical trial use: a RECIST perspective. J Immunother Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-005092.","DOI":"10.1136\/jitc-2022-005092"},{"issue":"4","key":"1012_CR14","doi-asserted-by":"publisher","first-page":"e26896","DOI":"10.1002\/pbc.26896","volume":"65","author":"LM Guenther","year":"2018","unstructured":"Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE. Response evaluation criteria in solid tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018;65(4):e26896. https:\/\/doi.org\/10.1002\/pbc.26896.","journal-title":"Pediatr Blood Cancer"},{"key":"1012_CR15","doi-asserted-by":"publisher","unstructured":"Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;JCO2300225. https:\/\/doi.org\/10.1200\/JCO.23.00225.","DOI":"10.1200\/JCO.23.00225"},{"key":"1012_CR16","doi-asserted-by":"publisher","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, et al. Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023;308. https:\/\/doi.org\/10.1148\/radiol.222148.","DOI":"10.1148\/radiol.222148"},{"key":"1012_CR17","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1111\/1759-7714.14207","volume":"12","author":"WK Ryu","year":"2021","unstructured":"Ryu WK, Kim JS, Park MH, Lee M, Kim HJ, Ryu JS, Lim JH. Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non-small-cell lung cancer. Thorac Cancer. 2021;12:3333\u20139. https:\/\/doi.org\/10.1111\/1759-7714.14207.","journal-title":"Thorac Cancer"},{"key":"1012_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12916-016-0729-9","volume":"14","author":"SM Crusz","year":"2016","unstructured":"Crusz SM, Tang YZ, Sarker S-J, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, et al. Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med. 2016;14:185. https:\/\/doi.org\/10.1186\/s12916-016-0729-9.","journal-title":"BMC Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01012-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01012-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:16:35Z","timestamp":1772442995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01012-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01012-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study was approved by the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 22\u20130321). Because all patients had previously consented to the use of their data within the study registry, the requirement for additional informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.v.B.-B. received research funding and honoraria from Novartis, Kite Pharma, Miltenyi Biotec, Mologen, MSD, Astellas, and Roche. W.G.K. served as advisor to Bristol Myers Squibb, Boehringer Ingelheim, mintMedical and Need, Inc.. The remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}